Sugi Predict

Sugi Predict / Targets / PELP1

PELP1

Proline-, glutamic acid- and leucine-rich protein 1 · Q8IZL8 · PELP1 on Sugi Atlas →

762 patent compounds predicted against PELP1, 532 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12068709 SCHEMBL12068709 1.00 1/20
SCHEMBL12068668 SCHEMBL12068668 0.89 1/20
SCHEMBL15236235 SCHEMBL15236235 0.89 1/20
SCHEMBL12068675 SCHEMBL12068675 0.82 1/20
SCHEMBL12068651 SCHEMBL12068651 0.74 1/20
SCHEMBL12068696 SCHEMBL12068696 0.74 1/20
SCHEMBL12068672 SCHEMBL12068672 0.72 1/20
SCHEMBL12068713 SCHEMBL12068713 0.72 1/20
SCHEMBL15025696 SCHEMBL15025696 0.72 1/20
SCHEMBL15799946 SCHEMBL15799946 0.72 1/20
SCHEMBL15799947 SCHEMBL15799947 0.72 1/20
SCHEMBL12068656 SCHEMBL12068656 0.72 1/20
SCHEMBL12068664 SCHEMBL12068664 0.72 1/20
SCHEMBL12068699 SCHEMBL12068699 0.72 1/20
SCHEMBL12070194 SCHEMBL12070194 0.72 1/20
SCHEMBL12068657 SCHEMBL12068657 0.71 1/20
SCHEMBL12070180 SCHEMBL12070180 0.71 1/20
SCHEMBL12068691 SCHEMBL12068691 0.71 1/20
SCHEMBL20428931 SCHEMBL20428931 0.71 1/20
SCHEMBL16392518 SCHEMBL16392518 0.71 1/20

Clinical trials — most relevant to PELP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Aswan Heart Centre - Egyptian Healthy Volunteers nanRECRUITING
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods nanUNKNOWN
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations nanUNKNOWN
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa nanUNKNOWN
Explore the Role of NLRP7 in the Regulation of Progestereone Induced Decidualization of Human Endometrial Stroma Cells nanCOMPLETED
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment nanUNKNOWN
Proteomic and Histological Analysis of Ligamentum Flavum in Lumbar Stenosis nanRECRUITING
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy nanUNKNOWN
Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis nanUNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PELP1 binder may also engage these)

ProteinNameSimilarity
Q1W1Y5 — 1.000 Q1W1Y5 →
Q9DBD5 — 0.998 Q9DBD5 →
Q56B11 — 0.997 Q56B11 →
Q58HI1 — 0.992 Q58HI1 →
Q3T1I9 — 0.988 Q3T1I9 →
Q8VDP4 — 0.988 Q8VDP4 →
Q3UJB9 — 0.987 Q3UJB9 →
Q8K330 — 0.986 Q8K330 →
A2AEV7 — 0.986 A2AEV7 →
O70405 — 0.985 O70405 →
A0A8I3PMN2 — 0.985 A0A8I3PMN2 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.985 landscape →
Q66K74 — 0.985 Q66K74 →
Q6ZQA0 — 0.985 Q6ZQA0 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.985 landscape →
Q8CHT3 — 0.985 Q8CHT3 →
O18805 — 0.985 O18805 →
A0JN53 — 0.984 A0JN53 →
Q76LL6 — 0.984 Q76LL6 →
A2A699 — 0.984 A2A699 →
Q5T124 — 0.984 Q5T124 →
Q96C34 — 0.984 Q96C34 →
Q9BQK8 — 0.984 Q9BQK8 →
Q9Y4B5 — 0.984 Q9Y4B5 →
O75064 — 0.984 O75064 →
Q9BQI7 — 0.983 Q9BQI7 →
A1A4J7 — 0.983 A1A4J7 →
Q8K3T3 — 0.983 Q8K3T3 →
O43299 — 0.983 O43299 →
Q9P1Y5 — 0.983 Q9P1Y5 →